Table 1:
Descriptive statistics of 4145 included patients with stage IV GBC from the NCDB.
| Age at Diagnosis | Mean | 68.06 |
| Median | 69 | |
| Minimum | 24 | |
| Lower Quartile | 60 | |
| Upper Quartile | 77 | |
| Interquartile Range | 17 | |
| Maximum | 90 | |
| Standard Deviation | 11.96 | |
| Missing | 0 | |
| Category | Value | N (%) |
| Sex | Male | 1213 (29.3) |
| Female | 2932 (70.7) | |
| Race category, 3-levels | White | 3289 (79.3) |
| Black | 575 (13.9) | |
| Asian/Other | 281 (6.8) | |
| Charlson-Deyo Score | 0 | 2905 (70.1) |
| 1 | 918 (22.1) | |
| 2+ | 322 (7.8) | |
| Year of Diagnosis | 2004–2010 | 2104 (50.8) |
| 2011–2015 | 2041 (49.2) | |
| Insurance Status (3-level category) | Not insured | 179 (4.4) |
| Private Insurance | 1282 (31.6) | |
| Public Insurance: Medicaid, Medicare, Other Government | 2602 (64.0) | |
| Missing | 82 | |
| Facility Type | Community Cancer Program | 387 (9.5) |
| Comprehensive Community Cancer Program | 1628 (39.9) | |
| Academic/Research Program | 1525 (37.3) | |
| Integrated Network Cancer Program | 545 (13.3) | |
| Missing | 60 | |
| Histology | 8020: Undifferentiated, NOS | 14 (0.3) |
| 8050: Papillary Type Carcinoma | 4 (0.1) | |
| 8070: Epidermoid Type Carcinoma | 54 (1.3) | |
| 8071: Squamous Cell Carcinoma | 8 (0.2) | |
| 8140: Adenocarcinoma | 3693 (89.1) | |
| 8255: Adenocarcinoma, mixed sub-type | 38 (0.9) | |
| 8260: Papillary Adenoma | 55 (1.3) | |
| 8480: Adenocarcinoma, Mucinous sub-type | 138 (3.3) | |
| 8560: Adenocarcinoma, mixed subtype (Adeno-squamous) | 141 (3.4) | |
| AJCC Pathologic T | p0/p1/p1A/p1B | 92 (2.4) |
| p2 | 755 (19.3) | |
| p3 | 1461 (37.4) | |
| p4 | 397 (10.2) | |
| pIS/pX | 1206 (30.8) | |
| Missing | 234 | |
| AJCC Pathologic N | p0 | 702 (18.2) |
| p1 | 876 (22.7) | |
| p2 | 218 (5.7) | |
| pX | 2057 (53.4) | |
| Missing | 292 | |
| AJCC Pathologic M | p1 | 3389 (96.1) |
| pX | 136 (3.9) | |
| Missing | 620 | |
| Treatment Started, Days from Diagnosis | Mean | 10.42 |
| Standard Deviation | 21.03 | |
| Definitive Surgical Procedure, Days from Diagnosis | Mean | 9.85 |
| Standard Deviation | 35.89 | |
| Surgical Margins Status at any CoC Facility | No residual tumor All margins are grossly and microscopically negative | 1010 (25.9) |
| Residual tumor, NOS Involvement is indicated, but not otherwise specified | 582 (14.9) | |
| Microscopic residual tumor Cannot be seen by the naked eye | 529 (13.6) | |
| Macroscopic residual tumor, Gross tumor of the primary site which is visible to the naked eye | 180 (4.6) | |
| Margins not evaluable, Cannot be assessed (indeterminate) | 145 (3.7) | |
| No primary site surgery | 1456 (37.3) |